Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 64400141

Drug Profile

JNJ 64400141

Alternative Names: Ad26-RSV-preF; Ad26.RSV.preF; Ad26.RSV.preF-based vaccine; Adenovirus Serotype 26 (Ad26.RSV.preF)-based vaccine; JNJ-64400141; RSV Jr prophylactic vaccine - Janssen; RSV Senior prophylactic vaccine - Janssen; VAC-18193; VAC-18194

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Vaccines and Prevention B.V
  • Class Respiratory syncytial virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 03 Aug 2023 Janssen Vaccine and Prevention completes a phase II CYPRESS trial in Respiratory syncytial virus infections (Prevention, In the elderly) in USA (IM) (NCT03982199)
  • 17 May 2023 Janssen Pharmaceutical terminates a phase III trial in Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Japan (IM) due to sponsor's decision (NCT05242432)
  • 30 Mar 2023 Discontinued - Phase-III for Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Germany, USA, Poland, Estonia, Canada, Australia, Brazil, Chile, China, Finland, New Zealand, South Africa, Taiwan, Thailand (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top